Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaIRS Trial: Cabozantinib + High-dose Ifosfamide in Relapsed/Refractory Sarcomas
NCT06156410Phase 1Recruiting
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Oct 2023
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabozantinib in sarcoma, Ewing sarcoma and osteosarcoma (OS), sponsored by Children's Hospital of Philadelphia. Primary endpoint: Maximum Tolerated Dose / Recommended Phase II Dose at 1 year. Started Oct 2023; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
sarcomaEwing sarcomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT06156410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06156410.